Article
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
The Journal of clinical investigation - 1 Sept 2016
Xu Jianing, Pham Can G, Albanese Steven K, Dong Yiyu, Oyama Toshinao, Lee Chung-Han, Rodrik-Outmezguine Vanessa, Yao Zhan, Han Song, Chen David, Parton Daniel L, Chodera John D, Rosen Neal, Cheng Emily H, Hsieh James J
Abstract excerpt
Genomic studies have linked mTORC1 pathway-activating mutations with exceptional response to treatment with allosteric inhibitors of mTORC1 called rapalogs. Rapalogs are approved for selected cancer types, including kidney and breast cancers. Here, we used sequencing data from 22 human kidney cancer cases to identify the activating mechanisms conferred by mTOR mutations observed in human cancers and advance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.